NAMS

NewAmsterdam Pharma Company
NAMS

Latest price

Financial Snapshot

gainify

Market Data

Market Cap
$1.90B
EV
$1.06B
Shares Outstanding
118.66M
Beta
-0.00

Wall Street View

Analyst Rating
BUY
Analyst Target Price
$46.89
P/E 2025E
-
P/Revenue 2025E
104.83x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About NewAmsterdam Pharma Company N.V.

gainify
NAMS

NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in v...

Sector

Healthcare

Industry

Biotechnology

CEO

Davidson, Michael

Employees

68

IPO Date

2021-02-09

Headquarters

Gooimeer 2-35, Naarden, Noord-Holland, 1411 DC, Netherlands

gainify
mailcontactcontact
powered-by-sp

NEWSLETTER

COMPANY

© Copyright 2025, All Rights Reserved